The Janssen Pharmaceutical Companies of Johnson & Johnson received aproval from U.S. FDA for CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.   CA...